MX2022001817A - Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas. - Google Patents

Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas.

Info

Publication number
MX2022001817A
MX2022001817A MX2022001817A MX2022001817A MX2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A MX 2022001817 A MX2022001817 A MX 2022001817A
Authority
MX
Mexico
Prior art keywords
mtbr
tau
microtube
methods
binding region
Prior art date
Application number
MX2022001817A
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Barthelemy
Randall Bateman
Kanta Horie
Chihiro Sato
Original Assignee
Washington University St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis filed Critical Washington University St Louis
Publication of MX2022001817A publication Critical patent/MX2022001817A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2022001817A 2019-08-13 2020-08-13 Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas. MX2022001817A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962886165P 2019-08-13 2019-08-13
US202062970950P 2020-02-06 2020-02-06
US202063044836P 2020-06-26 2020-06-26
PCT/US2020/046224 WO2021030615A1 (en) 2019-08-13 2020-08-13 Methods to detect mtbr tau isoforms and use thereof

Publications (1)

Publication Number Publication Date
MX2022001817A true MX2022001817A (es) 2022-03-11

Family

ID=74570452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001817A MX2022001817A (es) 2019-08-13 2020-08-13 Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas.

Country Status (10)

Country Link
US (1) US20220299527A1 (enExample)
EP (1) EP4013772A4 (enExample)
JP (2) JP7780200B2 (enExample)
KR (1) KR20220062287A (enExample)
CN (1) CN114555631A (enExample)
AU (1) AU2020331020A1 (enExample)
CA (1) CA3147548A1 (enExample)
IL (1) IL290492A (enExample)
MX (1) MX2022001817A (enExample)
WO (1) WO2021030615A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4096694A4 (en) 2020-01-30 2024-01-24 Prognomiq Inc LUNG BIOMARKERS AND THEIR METHODS OF USE
CN117460954A (zh) * 2021-03-31 2024-01-26 华盛顿大学 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况
US20220328134A1 (en) 2021-03-31 2022-10-13 PrognomIQ, Inc. Multi-omic assessment
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
AU2022341187A1 (en) 2021-09-13 2024-03-21 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
WO2023220276A1 (en) * 2022-05-11 2023-11-16 Washington University METHODS TO DETECT Aβ PROTEOFORMS AND USE THEREOF
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2024107745A1 (en) * 2022-11-14 2024-05-23 Washington University Methods to detect csf mtbr-tau and uses thereof
CN118896992A (zh) * 2024-08-30 2024-11-05 南京质谱医学科技有限公司 p-Tau217蛋白或其片段的检测方法、试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CA2867338A1 (en) 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
JP6345655B2 (ja) * 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
EP3674711A3 (en) 2014-07-01 2020-10-28 Steven W. Graves Biomarkers and methods for determining risk factors for alzheimer's disease
US10830775B2 (en) * 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
HRP20210124T1 (hr) * 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
EA037092B1 (ru) * 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
WO2017053739A1 (en) 2015-09-25 2017-03-30 Steen Judith Methods and compositions for tauopathy diagnosis and treatment
WO2018148593A1 (en) * 2017-02-10 2018-08-16 C2N Diagnostics, Llc Methods for measuring concentrations of biomolecules in biofluids
CN112166117A (zh) * 2018-05-03 2021-01-01 华盛顿大学 基于位点特异性tau磷酸化的诊断和治疗方法

Also Published As

Publication number Publication date
AU2020331020A1 (en) 2022-03-03
KR20220062287A (ko) 2022-05-16
JP2026048659A (ja) 2026-03-17
CN114555631A (zh) 2022-05-27
JP2022544514A (ja) 2022-10-19
WO2021030615A1 (en) 2021-02-18
EP4013772A1 (en) 2022-06-22
JP7780200B2 (ja) 2025-12-04
US20220299527A1 (en) 2022-09-22
IL290492A (en) 2022-04-01
CA3147548A1 (en) 2021-02-18
EP4013772A4 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
Zetterberg Tau in biofluids–relation to pathology, imaging and clinical features
Sämgård et al. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Kanaan et al. Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy
CO2025003552A2 (es) Anticuerpos anti-tau mtbr y métodos para detectar fragmentos escindidos de tau y usos de los mismos
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
MX2018001697A (es) Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.
Pluta et al. Lymphocytes, platelets, erythrocytes, and exosomes as possible biomarkers for Alzheimer’s disease clinical diagnosis
MX2022001087A (es) Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
Melief et al. Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of A lzheimer's disease
Zetterberg et al. Chronic traumatic encephalopathy: fluid biomarkers
Mizrahi et al. Gender and the functional outcome of elderly ischemic stroke patients
CO2023010786A2 (es) Métodos para detectar especies de csf tau con estado y progresión de la enfermedad de alzheimer, y uso de los mismos
BR112022003686A2 (pt) Tratamento de sintomas induzidos pelo ciclo menstrual
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
Clement et al. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models
Kranaster et al. Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression
CL2025001424A1 (es) Métodos para detectar mtbr-tau en lcr y sus usos
Vegas-Gomez et al. Peripheral administration of blood from tau transgenic animals exacerbates brain tau-associated pathology
Jain et al. Study of Cognitive Impairment and Depression in end Stage Renal Disease (Esrd) Patients
CL2023002887A1 (es) Perfiles de tau fosforilada y beta amiloide en csf como biomarcadores de tauopatías
Bing et al. 1156P Exosomal lncRNA HOTTIP assessment for non-small cell lung cancer surveillance after curative-intent surgery
Matos et al. Encouraging preclinical findings regarding the relationship between sleep and epilepsy